Microbiome Movement Summit on November 09-11, 2026 in Boston, United States

Translating Advanced Microbiome Science into Clinical and Commercial Impact, to Build Investor Confidence and Deliver Safe, Effective Solutions for End Consumers.

Momentum is returning to microbiome-based therapies. Companies like Vedanta Biosciences, Siolta Therapeutics, Microbiotica and Seres Therapeutics are moving closer to commercialisation across C. diff, oncology and immune-related diseases. Recent financings, including mbiomics (€30M), Kanvas Biosciences ($48M) and EnteroBiotix (£19M), alongside the Gates Foundation’s $2.5 billion commitment to women’s health, signal growing confidence in the field.

But momentum alone isn’t enough. Unclear mechanisms, inconsistent clinical efficacy, and limited pharma and investor trust still stand between promising science and real-world patient impact.

That’s why the 11th Microbiome Movement USA Summit returns to Boston this November. You will join C-suite, VP and Director-level leaders across pioneering biopharma, regulators, and both microbiome-curious and first-time investors to answer one critical question:

How do you translate microbiome biology into clinically validated, commercially viable therapies to effectively treat your indication of interest?

Don’t miss networking opportunities and insights from Ferring Pharmaceuticals, Nestlé Health Science, Vedanta Biosciences, MRM Health, Seventure Partners, The Gates Foundation, and more, as you discover how to demonstrate robust clinical efficacy, rebuild stakeholder confidence, and position your program for regulatory and commercial success.

URLs:

Tickets: https://go.evvnt.com/3721272-1?pid=10008

Brochure: https://go.evvnt.com/3721272-3?pid=10008

Time: 8:00 AM - 6:00 PM

Prices:

Drug Developer Pricing - Conference + 2 Workshops: USD 3597.00,

Drug Developer Pricing - Conference + 1 Workshop: USD 3148.00,

Drug Developer Pricing - Conference Only: USD 2699.00,

Start-Up and Academic Pricing - Conference + 2 Workshops: USD 2997.00,

Start-Up and Academic Pricing - Conference + 1 Workshop: USD 2648.00,

Start-Up and Academic Pricing - Conference Only: USD 2299.00,

Service Provider Pricing - Conference + 2 Workshops: USD 4797.00,

Service Provider Pricing - Conference + 1 Workshop: USD 4098.00,

Service Provider Pricing - Conference Only: USD 3399.00

Speakers: Bharat Dixit, Chief Technology Officer, Adiso Therapeutics, Todd Krueger, Chief Executive Officer, AOBiome, Daniel Brownell, Senior Director - Research and Development, AOBiome Therapeutics, Benjamin Hadida, Co-Founder and Chief Executive Officer, Exeliom Biosciences, Ken Blount, Senior Vice President, Head of Microbiome Clinical and Product Development, Ferring Pharmaceuticals, Alexander Khoruts, Chief Medical Officer, Gut-Brain Axis Therapeutics, Philip Burnham, Chief Scientific Officer, Kanvas Biosciences, Jun Terauchi, Chief Scientific Officer, Metagen Therapeutics, Katja Conrath, Chief Scientific Officer, MRM Health, Jason Goldsmith, Senior Director - Medical, Translational, and Data Sciences, Nestle Health Science, Eddie Moradian, Chief Executive Officer, Salspera, Elizabeth Halvorsen, Vice President - Translational Biology, Seres Therapeutics, Kelsey Wheeler, Founder and Chief Executive Officer, Tulip Biosciences, Dan Couto, Chief Operating Officer, Vedanta Biosciences, Bernat Olle, Chief Executive Officer, Vedanta Biosciences, Henry Haiser, Operating Partner, Corundum Systems Biology, Sathya Janardhanan, Venture Partner, Ecphora Capital, Denise Kelly, Investment Advisor, Seventure Partners, Vanessa Ridaura, Senior Program Officer - Microbiome Products, The Gates Foundation, Andrew Bartko, Executive Director, Center for Microbiome Innovation, Maria Andrea Azcarate Peril, Professor of Microbiology, University of North Carolina - Chapel Hill, Paul Carlson, Principal Investigator, US Food and Drug Administration (FDA), Giana Jarrah, Founder and Chief Executive Officer, Meraki Co, Momchilo (Momo) Vuyisich, Founding Chief Science Officer and Head of Clinical Research, Viome